C1q (classical complement cascade initiator) is upregulated in AD brain and tags synapses for microglial phagocytosis via C3-CR3 signaling. This excessive, activity-independent pruning underlies early synaptic loss before plaque deposition. The hypothesis is supported by compelling mechanistic studies (Hong et al. 2016) and Annexon Pharmaceuticals' ANX005 antibody is in clinical development. The mechanism explains early cognitive decline independent of amyloid burden, addressing a critical therapeutic gap. However, the complement system has pleiotropic functions—C1q also mediates protective synaptic plasticity and immune defense. Timing is critical: blocking C1q in prodromal AD may prevent pruning while later intervention may disrupt essential CNS maintenance.
No AI visual card yet
Curated Mechanism Pathway
Curated pathway diagram from expert analysis
flowchart TD
A["Complement C1Q Synaptic Tagging"]
B["C1QA C1QB C1QC Subcomponent Cascade"]
C["Microglial Phagocytosis Synapse Recognition"]
D["Early Synaptic Pruning"]
E["Cognitive Decline in Early AD"]
F["C1Q-Mediated Pruning as Driver"]
A --> B
B --> C
C --> D
D --> E
E --> F
style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style E fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style F fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
Median TPM across 13 brain regions for C1Q from GTEx v10.
Dimension Scores
How to read this chart:
Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential.
The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength),
green shows moderate-weight factors (safety, competition), and
yellow shows supporting dimensions (data availability, reproducibility).
Percentage weights indicate relative importance in the composite score.
7 citations3 with PMIDValidation: 0%4 supporting / 3 opposing
✓For(4)
No supporting evidence
No opposing evidence
(3)Against✗
HighMediumLow
HighMediumLow
Evidence Matrix — sortable by strength/year, click Abstract to expand
Evidence Types
5
2
MECH 5CLIN 2GENE 0EPID 0
Claim
Stance
Category
Source
Strength ↕
Year ↕
Quality ↕
PMIDs
Abstract
C1q mediates synapse loss in AD models; PMID 27488…
ANX005 (Annexon) in Phase I/II with acceptable safety profile
✗ Opposing Evidence
3
C1q has essential immune functions—systemic inhibition may increase infection risk
Complement inhibition may impair protective synaptic plasticity and CNS repair
Late-stage intervention unlikely to reverse established synaptic loss
Multi-persona evaluation:
This hypothesis was debated by AI agents with complementary expertise.
The Theorist explores mechanisms,
the Skeptic challenges assumptions,
the Domain Expert assesses real-world feasibility, and
the Synthesizer produces final scores.
Expand each card to see their arguments.
🧬TheoristProposes novel mechanisms and generates creative hypotheses▼
Theoretical Analysis: C1q-Driven Synaptic Pruning in Alzheimer's Disease
Key Molecular Mechanisms
C1q initiates the classical complement cascade, binding directly to synapses in an activity-independent manner—distinct from developmental pruning, which selectively eliminates less-active terminals. This pathway operates through sequential molecular events:
C1q deposition: Upregulated by astrocytes and neurons in AD brain, binding exposed phosphatidylserine on stressed synapses (Hong et al. 2016, PMID 27339137)
C3 convertase formation: C1q triggers C4/C2 cleavage, genera
🔍SkepticIdentifies weaknesses, alternative explanations, and methodological concerns▼
The hypothesis presents an elegant mechanistic framework linking amyloid oligomers to complement-driven synaptic loss, with therapeutic translation via ANX005. While the molecular pathway is biologically plausible and supported by experimental data, the theoretical analysis contains significant weaknesses that warrant scrutiny.
1. Causal Direction Remains Unresolved
The hypothesis assumes C1q upregulation drives synaptic loss in AD. However, C1q has established roles in synaptic maintenance and pr
🎯Domain ExpertAssesses practical feasibility, druggability, and clinical translation▼
Practical Translation Assessment: C1q as a Therapeutic Target in AD
Druggability — Favorable but Complex
C1q is a well-characterized target with validated biology. ANX005 (Anixa Biosciences), a monoclonal antibody against C1q, represents the primary clinical asset. It completed a Phase 1 study (NCT04592302) in healthy volunteers establishing initial safety and pharmacokinetic profiles. The company subsequently explored ALS (NCT05037964), but AD-specific development remains early-stage. Preclinical data in mouse models demonstrated reduced synaptic loss and preserved cognition, with
⚖SynthesizerIntegrates perspectives and produces final ranked assessments▼
{"hypothesis_title": "Complement C1q-Mediated Synaptic Pruning Drives Early Cognitive Decline in Alzheimer's Disease","synthesis_summary": "The C1q-mediated synaptic pruning hypothesis presents a mechanistically compelling framework linking amyloid oligomers to complement-driven synapse loss through microglial phagocytosis via C3-CR3 signaling. While the molecular pathway is biologically plausible and supported by strong preclinical data including Hong et al. 2016, significant concerns remain about causal direction and whether complement activation represents a primary driver or a secondary
Structured peer reviews assess evidence quality, novelty, feasibility, and impact. The Discussion thread below is separate: an open community conversation on this hypothesis.
IF prodromal AD patients (MCI due to AD, amyloid-positive) receive ANX005 (anti-C1q antibody) at 60mg/kg IV weekly for 12 months, THEN synaptic integrity markers in CSF (neurogranin, SNAP-25) will remain stable or increase compared to placebo-treated controls.
pendingconf: 0.72
Expected outcome: CSF neurogranin levels will remain within 10% of baseline in the ANX005 arm versus showing ≥15% increase (indicating synaptic loss) in the placebo arm within 12 months
Falsified by: Synaptic markers increase ≥15% in both ANX005 and placebo groups with no significant difference, indicating C1q blockade does not affect synaptic integrity in humans or the mechanism is not operative in prodromal AD
Method: Phase 2 randomized controlled trial (NCT05113966 or similar), n≥120 prodromal AD patients with biomarker-confirmed amyloid pathology, repeated CSF sampling at baseline and 12 months
IF early cognitive decline in AD is driven by C1q-mediated synaptic pruning independent of amyloid, THEN CSF C1q concentration will positively correlate with synaptic loss markers (neurogranin, GAP-43) and negatively correlate with cognitive scores (ADAS-Cog13) at baseline in amyloid-positive MCI patients, but show no correlation with amyloid PET standardized uptake value ratio.
pendingconf: 0.65
Expected outcome: Baseline CSF C1q will show r≥0.30 correlation with neurogranin and r≤-0.25 correlation with ADAS-Cog13, while showing r<0.10 correlation with amyloid PET SUVR in a cohort of ≥200 amyloid-positive MCI subjects
Falsified by: CSF C1q shows no significant correlation with synaptic markers (r<0.15) OR shows equal or stronger correlation with amyloid burden compared to synaptic markers, indicating amyloid rather than C1q drives cognitive decline
Method: Multicenter observational cohort study analyzing baseline CSF C1q (ELISA), synaptic biomarkers (neurogranin, GAP-43), amyloid PET imaging, and cognitive testing in amyloid-positive MCI participants from the Alzheimer's Clinical Trial Consortium or similar registry